KR20090087095A - 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제 - Google Patents
조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제 Download PDFInfo
- Publication number
- KR20090087095A KR20090087095A KR1020097013352A KR20097013352A KR20090087095A KR 20090087095 A KR20090087095 A KR 20090087095A KR 1020097013352 A KR1020097013352 A KR 1020097013352A KR 20097013352 A KR20097013352 A KR 20097013352A KR 20090087095 A KR20090087095 A KR 20090087095A
- Authority
- KR
- South Korea
- Prior art keywords
- enzyme
- dnase
- patients
- tissues
- deoxyribonucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 108020004414 DNA Proteins 0.000 title claims abstract description 28
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 26
- 102000053602 DNA Human genes 0.000 title claims abstract description 14
- 210000001519 tissue Anatomy 0.000 title claims abstract description 13
- 210000001723 extracellular space Anatomy 0.000 title claims abstract description 11
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 43
- 102000004190 Enzymes Human genes 0.000 claims abstract description 38
- 108090000790 Enzymes Proteins 0.000 claims abstract description 38
- 210000000056 organ Anatomy 0.000 claims abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000037396 body weight Effects 0.000 claims abstract description 6
- 239000003826 tablet Substances 0.000 claims description 22
- 239000002552 dosage form Substances 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 8
- 229940034610 toothpaste Drugs 0.000 claims description 7
- 239000000606 toothpaste Substances 0.000 claims description 7
- 229940112822 chewing gum Drugs 0.000 claims description 6
- 235000015218 chewing gum Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 4
- 239000006190 sub-lingual tablet Substances 0.000 claims description 4
- 229940098466 sublingual tablet Drugs 0.000 claims description 3
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 210000002429 large intestine Anatomy 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000006215 rectal suppository Substances 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 229940088598 enzyme Drugs 0.000 description 26
- 108010086613 Streptodornase and Streptokinase Proteins 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 7
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 7
- 238000011835 investigation Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 5
- 229960001225 rifampicin Drugs 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 239000004365 Protease Substances 0.000 description 4
- 108010023197 Streptokinase Proteins 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 230000019100 sperm motility Effects 0.000 description 3
- 229960005202 streptokinase Drugs 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 108010004032 Bromelains Proteins 0.000 description 2
- 230000007064 DNA hydrolysis Effects 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 235000019835 bromelain Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000006503 Amebic Liver Abscess Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010063741 Hepatic amoebiasis Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 125000000309 desoxyribosyl group Chemical class C1(C[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/RU2006/000642 WO2008066403A1 (fr) | 2006-11-28 | 2006-11-28 | Procédé de traitement de maladies humaines accompagnées d'une teneur plus élevée d'adn dans des espaces intercellulaires et préparation médicamenteuse destinée à sa mise en oeuvre |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20090087095A true KR20090087095A (ko) | 2009-08-14 |
Family
ID=39468110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097013352A Withdrawn KR20090087095A (ko) | 2006-11-28 | 2006-11-28 | 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8871200B2 (https=) |
| EP (1) | EP2095825B8 (https=) |
| JP (1) | JP5372769B2 (https=) |
| KR (1) | KR20090087095A (https=) |
| AT (1) | ATE513557T1 (https=) |
| ES (1) | ES2369547T3 (https=) |
| IL (1) | IL199005A (https=) |
| PL (1) | PL2095825T3 (https=) |
| WO (1) | WO2008066403A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006130034A1 (fr) * | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| US9248166B2 (en) | 2003-07-14 | 2016-02-02 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| US8710012B2 (en) * | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| US8871200B2 (en) | 2006-11-28 | 2014-10-28 | Cls Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| WO2011033689A1 (en) | 2009-09-18 | 2011-03-24 | Nippon Kayaku Kabushiki Kaisha | Catalyst and process for preparing acrolein and/or acrylic acid by dehydration reaction of glycerin |
| US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
| US11225648B2 (en) | 2015-01-04 | 2022-01-18 | Protalix Ltd. | Modified DNase and uses thereof |
| ES2799515T3 (es) * | 2015-05-22 | 2020-12-18 | Dmitry Dmitrievich Genkin | ADN extracelular como una diana terapéutica en la neurodegeneración |
| EP3359657B1 (en) | 2015-10-07 | 2020-04-01 | Novozymes A/S | Polypeptides |
| WO2018197547A1 (en) | 2017-04-25 | 2018-11-01 | Lipoxen Technologies Limited | Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i |
| AU2019209770B2 (en) | 2018-01-16 | 2025-07-31 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
| US12480150B2 (en) | 2018-06-29 | 2025-11-25 | Viktor Veniaminovich Tets and Georgy Viktorovich TETS | Compositions for modulating gut microbiota |
| US20200046809A1 (en) * | 2018-08-07 | 2020-02-13 | Bradley G. Thompson | Methods for regulating endogenous production of dnase1 |
| WO2020131952A1 (en) * | 2018-12-17 | 2020-06-25 | Mynarcik Dennis C | Compositions and methods for removing dental calculi |
| US12478571B2 (en) | 2018-12-17 | 2025-11-25 | Pontis Biologics, Inc. | Enzyme based compositions and methods for removing dental calculi |
| EP4225903A1 (en) | 2020-10-07 | 2023-08-16 | Protalix Ltd. | Long-acting dnase |
| CN117999086A (zh) * | 2021-05-24 | 2024-05-07 | 普利纳斯技术公司 | 使用dna酶的治疗方案 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3224942A (en) | 1962-01-15 | 1965-12-21 | Rorer Inc William H | Anti-inflammatory, anti-edema and anti-thrombi drug |
| US3324002A (en) | 1962-09-17 | 1967-06-06 | Armour Pharma | Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids |
| JPS5826822A (ja) * | 1981-08-10 | 1983-02-17 | Kaken Pharmaceut Co Ltd | 慢性腎炎治療剤 |
| JPS61293927A (ja) * | 1986-06-18 | 1986-12-24 | Kaken Pharmaceut Co Ltd | 肝臓疾患予防治療剤 |
| US4985243A (en) | 1988-01-20 | 1991-01-15 | Ml Technology Ventures, L.P. | Composition and method for protecting against diseases caused by microorganisms |
| EP0449968B1 (en) * | 1988-12-23 | 1999-02-24 | Genentech, Inc. | Process for the preparation of human dnase |
| US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| DE4024530A1 (de) | 1990-08-02 | 1992-02-06 | Klinger & Co Dr | Verfahren zur bekaempfung von viren |
| FR2666096B1 (fr) * | 1990-08-21 | 1993-12-31 | Sfri Sa | Nouveau procede de dosage d'acide desoxyribonucleique present en position extracellulaire dans un milieu. |
| WO1993003709A1 (en) | 1991-08-16 | 1993-03-04 | Vical, Inc. | Composition and method for treating cystic fibrosis |
| US5484589A (en) * | 1992-04-20 | 1996-01-16 | Rufeld, Inc. | Anti-viral methods using RNAse and DNAse |
| NZ299257A (en) | 1992-06-08 | 2000-08-25 | Genentech Inc | Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase |
| AU7212694A (en) * | 1993-06-24 | 1995-01-17 | Rufeld, Inc. | Inhibition of human immunodeficiency virus reproduction by deoxyribonuclease i |
| CH686982A5 (fr) * | 1993-12-16 | 1996-08-15 | Maurice Stroun | Méthode pour le diagnostic de cancers. |
| RU2099080C1 (ru) | 1994-02-11 | 1997-12-20 | Дмитрий Иванович Финько | Способ предотвращения развития рака |
| ATE268605T1 (de) | 1994-03-04 | 2004-06-15 | Genentech Inc | Pharmazeutische akzeptabel dnase zusammensetzung |
| DE69533987T2 (de) * | 1994-05-20 | 2006-03-16 | Hisamitsu Pharmaceutical Co., Inc., Tosu | Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte |
| NZ331063A (en) | 1996-02-05 | 2000-03-27 | Inc Genentech | Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition |
| AU2324997A (en) * | 1996-03-15 | 1997-10-01 | Penn State Research Foundation, The | Detection of extracellular tumor-associated nucleic acid in blood plasma or ser um using nucleic acid amplification assays |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| US6524578B1 (en) | 1996-07-10 | 2003-02-25 | Scott E. Tackett | Use of nuclease to reduce wrinkles and discolorations in humans |
| US6455250B1 (en) * | 1997-12-11 | 2002-09-24 | The Regents Of The University Of California | Endonuclease compositions and methods of use |
| NZ509273A (en) | 1998-07-16 | 2003-05-30 | Res Dev Foundation | DNA-cleaving antitumor agents containing a benzimidazole derivative |
| US6465177B1 (en) * | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| JP2002530436A (ja) | 1998-11-25 | 2002-09-17 | ジェネティカ インコーポレイテッド | 増殖能を増強しかつ複製老化を防止する方法及び試薬 |
| WO2001012793A1 (en) * | 1999-08-17 | 2001-02-22 | Tanuma Sei Ichi | Novel deoxyribonuclease, gene encoding the same and use thereof |
| US6428785B1 (en) * | 1999-10-28 | 2002-08-06 | Immunolytics Inc. | Method and composition for treating prostate cancer |
| UA78486C2 (uk) | 1999-12-10 | 2007-04-10 | Хемджен Корпорейшн | Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти) |
| WO2001074905A1 (en) | 2000-04-03 | 2001-10-11 | Antisoma Research Limited | Compounds for targeting |
| RU2202109C1 (ru) | 2001-08-03 | 2003-04-10 | Научно-исследовательский институт неврологии РАН | Способ выявления степени нарушения реологических свойств крови |
| RU2207876C1 (ru) * | 2001-11-08 | 2003-07-10 | Ткаченко Виталий Васильевич | Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия |
| CA2516322C (en) * | 2002-02-18 | 2013-10-15 | University Of Southampton | Glycosaminoglycan-dnase combination therapy |
| RU2207676C1 (ru) | 2002-04-24 | 2003-06-27 | ООО "Предприятие "Контакт-1" | Плоский радиолокационный отражатель |
| DE10221194B4 (de) | 2002-05-13 | 2005-02-10 | Fryda, Waltraud, Dr.med. | Hyaluronidasehaltiges Hautpflegemittel |
| US20040001817A1 (en) * | 2002-05-14 | 2004-01-01 | Giampapa Vincent C. | Anti-aging nutritional supplement |
| RU2239442C1 (ru) | 2003-05-05 | 2004-11-10 | Красноярская государственная медицинская академия | Способ профилактики внутриутробных инфекций у детей |
| AU2003298972A1 (en) | 2003-07-14 | 2005-02-04 | Dmitry Dmitrievich Genkin | Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| US8388951B2 (en) * | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
| RU2269356C2 (ru) * | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
| US8710012B2 (en) * | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
| WO2006130034A1 (fr) | 2005-04-25 | 2006-12-07 | Dmitry Dmitrievich Genkin | Procede pour prolonger la duree de vie d'animaux ou de l'humain |
| RU2269358C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения генерализованных инфекций, вызываемых бактериями, или заболеваний, вызываемых грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, обусловленных мутациями генов соматических клеток |
| WO2005004904A1 (en) | 2003-07-14 | 2005-01-20 | Dmitry Dmitrievich Genkin | Method for treating diseases associated with modifications of qualitative and/ quantitative composition of blood extracellular dna (variants) |
| RU2269359C2 (ru) | 2004-03-12 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты) |
| US8431123B2 (en) * | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
| RU2239404C1 (ru) | 2003-09-17 | 2004-11-10 | Бессонов Дмитрий Михайлович | Способ профилактики старения организма человека |
| RU2269357C2 (ru) | 2004-03-12 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ замедления наступления болезненных состояний, связанных с увеличением возраста человека |
| RU2267329C2 (ru) | 2004-03-12 | 2006-01-10 | Дмитрий Дмитриевич Генкин | Способ лечения заболеваний, сопровождающихся изменениями качественного и/или количественного состава внеклеточной днк крови (варианты) |
| US9592277B2 (en) * | 2004-04-14 | 2017-03-14 | Avirid, Inc. | Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases |
| JP3989936B2 (ja) | 2005-04-07 | 2007-10-10 | 進 須永 | 抗腫瘍剤及び新規ｄｎアーゼ |
| EP2484768A3 (en) * | 2005-07-18 | 2012-11-21 | Protalix Ltd. | Mucosal or enteral administration of biologically active macromolecules |
| RU2308968C2 (ru) | 2005-07-19 | 2007-10-27 | Дмитрий Дмитриевич Генкин | Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации |
| EP2416156B1 (en) * | 2006-10-18 | 2015-12-30 | Periness Ltd. | Method for determining a male fertility status |
| US8871200B2 (en) | 2006-11-28 | 2014-10-28 | Cls Therapeutics Limited | Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method |
| GB0922006D0 (en) | 2009-12-17 | 2010-02-03 | Genome Res Ltd | Diagnostic |
| US20130243794A1 (en) | 2010-12-03 | 2013-09-19 | Beth Israel Deaconess Medical Center, Inc. | Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses |
-
2006
- 2006-11-28 US US12/516,440 patent/US8871200B2/en active Active
- 2006-11-28 AT AT06843990T patent/ATE513557T1/de not_active IP Right Cessation
- 2006-11-28 ES ES06843990T patent/ES2369547T3/es active Active
- 2006-11-28 KR KR1020097013352A patent/KR20090087095A/ko not_active Withdrawn
- 2006-11-28 JP JP2009539202A patent/JP5372769B2/ja not_active Expired - Fee Related
- 2006-11-28 EP EP06843990A patent/EP2095825B8/en active Active
- 2006-11-28 WO PCT/RU2006/000642 patent/WO2008066403A1/ru not_active Ceased
- 2006-11-28 PL PL06843990T patent/PL2095825T3/pl unknown
-
2009
- 2009-05-27 IL IL199005A patent/IL199005A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ATE513557T1 (de) | 2011-07-15 |
| PL2095825T3 (pl) | 2011-12-30 |
| US20100061971A1 (en) | 2010-03-11 |
| EP2095825A4 (en) | 2009-12-30 |
| ES2369547T3 (es) | 2011-12-01 |
| JP5372769B2 (ja) | 2013-12-18 |
| US8871200B2 (en) | 2014-10-28 |
| EP2095825A1 (en) | 2009-09-02 |
| IL199005A (en) | 2012-04-30 |
| EP2095825B8 (en) | 2012-03-28 |
| IL199005A0 (en) | 2010-02-17 |
| WO2008066403A1 (fr) | 2008-06-05 |
| ES2369547T8 (es) | 2012-01-05 |
| JP2010511039A (ja) | 2010-04-08 |
| EP2095825B1 (en) | 2011-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20090087095A (ko) | 조직의 세포외공간에서 증가된 데옥시리보핵산 함량과 관련된 인간 질병을 치료하는 방법 및 이 방법을 수행하기 위한 약학 제제 | |
| Lauritano et al. | Evaluation of the efficacy of a new oral gel as an adjunct to home oral hygiene in the management of chronic periodontitis. A microbiological study using PCR analysis | |
| Hu et al. | An injectable photopolymerizable chitosan hydrogel doped anti-inflammatory peptide for long-lasting periodontal pocket delivery and periodontitis therapy | |
| Xu et al. | Hyperoside ameliorates periodontitis in rats by promoting osteogenic differentiation of BMSCs via activation of the NF‐κB pathway | |
| RU2308968C2 (ru) | Способ лечения заболеваний человека, сопровождающихся повышенным содержанием дезоксирибонуклеиновой кислоты во внеклеточных пространствах тканей, и лекарственный препарат для его реализации | |
| US6727288B2 (en) | Method for treating bone fracture | |
| Vanditha et al. | Modulatory effect of probiotic fiber (Lactobacillus reuteri) in residual periodontal pockets: a randomized, double-blind, placebo-controlled study | |
| US11654167B2 (en) | Pharmaceutical composition based on bacteriophages against F. nucleatum; use in the treatment of diseases associated with this pathogen | |
| CN115813904A (zh) | 异泽兰黄素在治疗肝纤维化药物中的应用 | |
| Curtis Jr et al. | An apparent unusual relationship between rampant caries and the oral mucosal manifestations of chronic graft-versus-host disease | |
| Khazia et al. | Antifungal activity of combination of medicinal plant extracts with terbinafine through regulating subtilisin virulence genes in Microsporum canis. | |
| CN113557036A (zh) | 基因编辑以改善关节功能 | |
| WO2009105786A2 (en) | Treatment for oral disease | |
| IGAAP et al. | The effectiveness of giving snail slime (Acatina fulica) on the healing of pocket on the wistar rats with periodontitis | |
| Pratiwi et al. | Garlic extract effectivity against the viability of biofilms produced by streptococcus mutans serotypes c and f in pediatric patients with early childhood caries | |
| CN115820607A (zh) | 一种抗菌肽HeLyzG1及其编码序列和用途 | |
| TWI838163B (zh) | 預防及/或改善口腔黏膜下纖維化之組成物及其用途 | |
| KR102809527B1 (ko) | G 단백질 연결 수용체의 억제제를 이용한 상아질 재생 촉진용 조성물 및 제제 | |
| Jin et al. | Both live and heat-killed Bifidobacterium animalis J-12 alleviated oral ulcer of LVG golden Syrian hamsters by intervening intestinal flora structure | |
| CN121818771A (zh) | 一种中药组合物及其在口腔方面的应用 | |
| CN121311238A (zh) | 有助于改善口腔黏膜相关纤维化的产品 | |
| Yang et al. | Exploring the Potential of Ornidazole as an Alternative Treatment for Pulpitis: Effects on Dental Pulp Cells and Macrophages | |
| CN120271720A (zh) | 一种用于治疗鼻咽癌患者放疗后放射性口干的喷雾及其制备方法和应用 | |
| Hermiston | Development and validation of qPCR targets for porphyromonas gingivalis abundance and expression levels of genes in the human oral microbiome | |
| CN119235878A (zh) | D-甘露糖在制备治疗牙周炎产品中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20090626 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |